mobile nav button

Synergy Pharmaceuticals: Inventing the future for GI disease

Our Focus is on
Gastrointestinal Disease

Creating
Proprietary
Analogues
of a Natural
GI Hormone

Novel Compounds Target
GI Mucosa to Regulate
the Bowel

Digestive Disease Week 2013
Plecanatide Late Breaker Presentation

Now Enrolling

CIBS Study: Constipation-predominent Irritable Bowel Syndrome

Initiated in 2012, this multicenter study of plecanatide in patients with IBS-C is being conducted at 70 US sites, treating 350 patients.

How to enroll

Plecanatide:
A Novel Approach for GI Disease

Learn how this new class of drugs mimic a natural hormone to regulate the bowel.

Go Here

Synergy Pharmaceuticals

Synergy Pharmaceuticals is a publicly traded biopharmaceutical company dedicated to developing novel therapies for patients with gastrointestinal diseases and disorders. Discovered in-house by Synergy scientists, our proprietary compounds are being developed as new treatments for chronic idiopathic constipation, irritable bowel syndrome with constipation and inflammatory bowel diseases, with an immediate focus on ulcerative colitis.

Learn more